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Abstract
Background: Cardiac surgery in Jehovah’s Witnesses may be challenging during the operation and postoperative
period given their refusal of blood products. The aim of this study was to document our center’s experience with
Jehovah’s Witnesses undergoing major cardiac surgery and to compare surgical outcomes with a matched
control group.
Methods: We retrospectively reviewed the demographic, perioperative, and in-hospital postoperative data for 31
Jehovah’s Witness patients undergoing surgery from 1991 to 2012 and compared findings with a control group
of 62 patients of the same sex and age, who underwent the same type of operations in the same period. Early
mortality, major in-hospital morbidity, laboratory findings, and hospital stays were compared between groups.
Results: Demographic data were similar between groups, except that more patients in the Jehovah’s Witness
group had extracardiac arteriopathy compared with controls (p = 0.04). There was no difference in predicted
mortality, calculated by the Euroscore II, between groups (2.8 ± 3.3 in study group versus 2.4 ± 2.2 in control
group, p = 0.469). For postoperative outcomes, there were no differences between Jehovah’s Witnesses versus
controls in hospital mortality (3 % versus 2 %, p = 0.548), total drain loss (847 ± 583 mL versus 812 ± 365 mL,
p = 0.721), mechanical ventilation time (1.26 ± 2.24 versus 0.89 ± 0.55 days, p = 0.218), intensive care unit stay
(4.3 ± 3.9 versus 3 ± 1.4 days, p = 0.080), and hospital stay (12.9 ± 7.6 versus 10.9 ± 6.6 days, p = 0.223).
Conclusions: Outcomes after cardiac surgery are similar between Jehovah’s Witnesses and general population, in
centers applying rigorous blood patient management protocols.
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Background
Jehovah’s Witnesses refuse the transfusion of blood
products, based on Biblical passages citing to “abstain
from food polluted by idols, from sexual immorality,
from the meat of strangled animals and from blood”
(Acts 15:19–20). Before major surgery, these patients are
confronted with the stress of both the operation and the
potential need for transfusion. The role of the health
care provider is to assure the physical and psychological
welfare of patients while respecting their philosophical
and religious beliefs. However, despite the important
evolution of blood preservation techniques, there is still
a great risk for transfusion in cardiac surgery. Transfu-
sion rates during hospitalization for a cardiac surgery
procedure vary from 25 to 95 % [1–3]. In this context,
cardiac surgery in Jehovah’s Witnesses represents a real
challenge, necessitating a close collaboration between
the surgical, anesthesiological, and medical teams. How-
ever, due to the Jehovah’s Witnesses’ “natural experiment
of blood abstention”, the overall need for transfusion
during cardiac surgery should be reevaluated [4]. Recent
studies did not find any difference in terms of mortality
between Jehovah’s Witnesses and a control group after
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cardiac surgery [4–7]. Moreover, the deleterious effects
of blood transfusions in terms of postoperative morbidity
and long term mortality after cardiac surgery, along with
the cost and shortage of available blood products, suggest
tighter transfusion protocols [1, 2, 8–11]. In this context,
the investigation of surgical outcomes in Jehovah’s
Witnesses helps to evaluate the limits of transfusion
safety and cut off points for transfusion, while improving
the hospital care of this challenging group of patients [12].
The aim of this study was to document our center’s ex-
perience with complex cardiac surgery, including reopera-
tions and urgent operations, in a non-selected Jehovah’s
Witness group and to compare surgical outcomes with a
matched control group.
Methods
The current retrospective study was carried out by the
Cardiac Surgery Department of Brugmann University
Hospital in Brussels. All adult Jehovah’s Witness patients
operated in our hospital from 1991 to 2012 (n = 31) were
identified through our computerized database. Baseline
demographics, perioperative data, postoperative out-
comes, and laboratory data (Tables 1, 2, 3 and 4) were
recorded after consultation of each patient’s chart and
admission medical history. For each of the 31 Jehovah’s
Witnesses, the previous and the next patient of the same
sex who underwent the same surgical procedure were
included in the control group if their age difference from
the Jehovah’s Witness patient was ≤ 5 years. All patients
were operated on by the same surgical team consisting
of four senior surgeons (Table 1).
The same anesthesia protocol, surgical techniques,
extracorporeal circulation, myocardial protection, and
blood salvage techniques were used for both groups. A
coated circuit with open venous reservoir and a centrifugal
pump was used for extracorporeal circulation. Priming,
consisted of only 1 L of colloid solution (modified fluid
gelatin) and 150 mg of 20 % mannitol. Whenever patient’s
Table 1 Patients’ demographics
Jehovah’s Witnesses (n = 31) Control Group (n = 62) p Value
Age in years 62 ± 15 62 ± 14 0.873
BMI (kg/m2) 27.4 ± 4.3 26.2 ± 4.0 0.182
Women 10 (32 %) 20 (32 %) 1.000
Number of operations per surgeon (1, 2, 3,4) 13, 10, 4, 4 15, 27, 12, 8 0.344
Euroscore II 2.80 ± 3.34 2.38 ± 2.20 0.469
Preoperative Cockcroft’s CC in mL/min 84 ± 29 82 ± 27 0.776
Renal insufficiency (Cockcroft’s CC <85 mL/min) 16 (52 %) 34 (55 %) 0.769
Diabetes 8 (26 %) 15 (24 %) 0.865
Recent smoker 3 (10 %) 17 (27 %) 0.062
Hypertension 18 (58 %) 30 (48 %) 0.379
Hypercholesterolemia 19 (61 %) 36 (58 %) 0.765
Positive family history 10 (32 %) 18 (29 %) 0.749
Cerebrovascular accident 4 (13 %) 5 (9 %) 0.457
Peripheral vascular disease 8 (26 %) 6 (10 %) 0.040
Previous myocardial infarction 6 (19 %) 11 (18 %) 0.850
Recent myocardial infarction (<90 days) 3 (10 %) 6 (10 %) 1.000
COPD 6 (19 %) 6 (10 %) 0.189
NYHA 0.452
I 6 (19 %) 7 (11 %) -
II 12 (39 %) 21 (34 %) -
III 10 (32 %) 30 (48 %) -
IV 3 (10 %) 4 (6 %) -
Preoperative LVEF (%) 62 ± 11 59 ± 14 0.340
Preoperative AF 5 (16 %) 9 (15 %) 0.838
Reoperation 3 (10 %) 8 (13 %) 0.650
Urgent status 7 (23 %) 6 (10 %) 0.091
BMI body mass index, CC creatinine clearance, Recent smoker current smoker or ex-smoker for less than 5 years, COPD chronic obstructive pulmonary disease,
NYHA New York heart association score, AF atrial fibrillation, LVEF left ventricular ejection fraction
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hemodynamic state permitted it, retropriming technique
was used to further reduce hemodilution. All the patients
were maintained with an hematocrit up to 24 % and
hemofiltration was systematically performed. All the pro-
cedures were achieved under mild hypothermia (between
32 and 33 °C). The cardiopulmonary flow rate was main-
tained between 2,8 and 3 L/min/m2 and the FiO2
(inspired oxygen fraction) was adapted to maintain a
SvO2 (venous saturation in oxygen) above the 75 %
threshold.
From 1991 to 2007, aprotinin was routinely adminis-
tered in the priming solution as an antifibrinolytic
agent and replaced thereafter by tranexamic acid [13].
For all operations where the ascending aorta was
opened, retrograde cardioplegia was administered. For
operations with an intact aortic root and competent
aortic valve, anterograde cardioplegia was administered
from the ascending aorta. From 1991 to 2010, a modi-
fied Saint Thomas crystalloid cold cardioplegia was
used, subsequently replaced by a cold blood cardiople-
gia (8 °C) diluted with 23 % crystalloid solutions. Sig-
nificant blood loss was systematically processed with a
Cell Saver. For the Jehovah’s Witness group, a continu-
ous connection between the Cell Saver’s washed blood
bag and the patient’s peripheral intra-venous infusion
line was used in accordance with their beliefs for con-
tinuous blood flow.
After 2003, all Jehovah’s Witness patients undergoing
elective surgery were evaluated preoperatively to
optimize their red blood cell volume. When hemoglobin
was less than 13 g/dL, a total of three subcutaneous in-
jections of 40 000 units of erythropoietin and intraven-
ous iron were administered 3, 2, and 1 week before the
operation. Control group patients did not receive any
erythropoietin treatment, as it is not reimbursed by the
Belgium national health care system for cardiac surgery.
Oral anticoagulation therapy was routinely discontinued
3 days before surgery and replaced with fractionated
heparin. Platelet anti-aggregation therapy was routinely
discontinued 7 days before elective surgery cases [9, 10].
Univariate analysis of demographics as well as pre-
operative, operative, and postoperative in-hospital
variables was performed between the two groups.
Comparisons between continuous variables were per-
formed using the Student t-test after the Levene’s test
for equality of variances. Dichotomous variables were
compared using the χ2 or the Fisher’s exact test for
cell counts < 5. A p value ≤ 0.05 was considered signifi-
cant and all tests were 2-sided. All parametric data are
presented as the mean value ± standard deviation.
Statistical analysis was performed with SPSS 20.0.
Results
In our study, the Jehovah’s Witness group underwent a
variety of cardiac surgery procedures, included reopera-
tions and urgent procedures. The control group was
selected based on the type of surgical procedure as
described in the methods (Table 2). Demographic char-
acteristics of Jehovah’s Witnesses versus the controls
are presented in Table 1. Univariate analysis showed
that the groups had similar demographics and pre-
operative characteristics. The Euroscore II was calcu-
lated for both groups and there was no difference in
predicted mortality (p = 0.469). The left ventricular ejec-
tion fraction was also similar between groups (p = 0.340).
The only significant difference between groups was that
Jehovah’s Witnesses had more peripheral vascular disease
than controls (p = 0.040, Table 1).
Table 2 Type of surgery




CABG 15 (48 %) 30 (48 %)
CABG beating heart 2 (6 %) 4 (6 %)
AVR 5 (16 %) 10 (16 %)
MVR 2 (6 %) 4 (6 %)
Double VR 2 (6 %) 4 (6 %)
Combined VR + CABG 3 (10 %) 6 (10 %)
Bentall 1 (3 %) 2 (3 %)
AAR 1 (3 %) 2 (3 %)
CABG coronary artery bypass graft, AVR aortic valve replacement, MVR mitral
valve replacement, VR valve replacement, AAR ascending aortic replacement
Table 3 Laboratory findings
Hb (g/dL) Plat (× 1000/mm3) Cr (mg/dL)
JhW CG p JhW CG P JhW CG p
D−1 14.2 ± 1.6 13.7 ± 1.7 0.174 226.4 ± 55.2 233.7 ± 75 0.640 1.13 ± 0.29 1.08 ± 0.20 0.272
D0 10.6 ± 1.8 10.4 ± 1.3 0.478 156.3 ± 38.9 156.0 ± 47.4 0.974 1.13 ± 0.29 1.05 ± 0.22 0.112
D1 11.0 ± 2.0 10.9 ± 1.5 0.849 179.7 ± 50.8 179.3 ± 55.4 0.977 1.28 ± 0.48 1.15 ± 0.30 0.123
D2 10.5 ± 2.2 10.5 ± 1.2 0.995 177.9 ± 66.3 167.6 ± 58.3 0.468 1.18 ± 0.55 1.03 ± 0.41 0.160
D5 10.7 ± 2.5 11.0 ± 1.7 0.513 220.1 ± 85.5 227.5 ± 87.7 0.732 1.12 ± 0.53 1.03 ± 0.50 0.445
D7 10.7 ± 2.5 11.4 ± 1.8 0.218 298.9 ± 93.1 329 ± 106.7 0.301 1.17 ± 0.67 1.13 ± 0.69 0.862
JHW Jehovah’s witnesses, CG control group, Hb hemoglobin, Plat platelets, Cr creatinine, D−1 preoperative, D0-D7 Day 0-Day 7
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Hemoglobin, platelet, and serum creatinine values
were compared between groups one day preoperatively
and on days 0, 1, 2, 5, and 7 postoperatively and there
was no significant difference at any time between groups
(Table 3). Perioperative variables and postoperative out-
comes are grouped in Table 4. No difference was ob-
served in the time of extracorporeal circulation, aortic
clamping, or perioperative blood loss. Drains were with-
drawn within two days after the operation and their out-
put was similar between groups (p = 0.721). One patient
from each group underwent a reoperation for mediasti-
nitis (p = 1.000). Two reoperations for hemorrhage or
tamponade were performed in Jehovah’s Witnesses ver-
sus one in the control group (p = 0.257). No significant
difference was observed in postoperative renal function,
as defined by the maximum postoperative serum
creatinine (p = 0.378) and the minimum postoperative
creatinine clearance (p = 0.865). One Jehovah’s Witness
developed severe renal failure at day1 necessitating
hemodialysis. This patient developed multi-organ failure
in sepsis post-mediastinitis and died in the intensive care
unit on day 37 after a triple coronary artery bypass. This
patient suffered from insulin depending diabetes with a
preoperative logistic euroscore II of 15.09. Preoperative
creatinine level and estimated creatinine clearance were
respectively 2,04 mg/dL and 30,0 mL/min. He was oper-
ated in an urgent status because of a non ST elevation
myocardial infarction. Minimal hemoglobin level during
extracorporeal circulation was 9,4 gr/dL and minimal
hemoglobin level the day of the procedure was 8,4 gr/dL.
The hemoglobin level rose progressively up to 12,4 gr/dL
at postoperative day seven.
There was no significant difference in surgical out-
comes. Hospital mortality was 3 % for Jehovah’s Witnesses
versus 2 % for control group, p = 0.548. The postoperative
left ventricular ejection fraction was similar between
groups (p = 0.912). No stroke was observed in our series.
One control patient had acute myocardial infarction but
Table 4 Postoperative outcomes
Jehovah’s Witnesses Control group P value
Time of ECC in min 104 ± 35 98 ± 36 0.432
Cross Clamp Time in min 61 ± 27 59 ± 29 0.721
Perioperative blood loss in mL 209 ± 235 308 ± 367 0.178
Drain 24 h in mL 644 ± 458 582 ± 215 0.481
Drain total in mL 847 ± 583 812 ± 365 0.721
Hours post drain ablation 46.3 ± 9.8 45.7 ± 12.1 0.811
LVEF postop (%) 57 ± 8 58 ± 10 0.912
Mechanical ventilation in days 1.26 ± 2.24 0.89 ± 0.55 0.218
ICU stay in days 4.3 ± 3.9 3.0 ? ± 1.4 0.080
Postoperative length of stay in days 12.9 ± 7.6 10.9 ± 6.6 0.223
IABP 1 (3 %) 0 0.333
Acute MI 0 1 (2 %) 1.000
Stroke 0 0 -
New onset AF 11 (35 %) 11 (18 %) 0.058
New AF on discharge 0 3 (5 %) 0.548
Max Cr postop (mg/dL) 1.43 ± 0.60 1.32 ± 0.60 0.378
Min Cockcroft’s CC postop (mL/min) 63.8 ± 32.3 64.8 ± 24.8 0.865
Hemodialysis 1 (3 %) 0 0.333
Hemorrhage related re-exploration 2 (6 %) 1 (2 %) 0.257
Mediastinitis 1 (3 %) 1 (2 %) 1.000
Serious infectious complications 5 (16 %) 3 (5 %) 0.112
Transfused patients 0 17 (27.4 %) 0.001
Units of RBC 0 39 -
Units of RBC pp 0 ± 0 0.63 ± 1.5 0.002
Operative mortality 1 (3 %) 1 (2 %) 0.548
ECC extracorporeal circulation, ICU intensive care unit, LVEF left ventricular ejection fraction, postop = postoperative, RBC red blood cells, IABP intra-aortic balloon
pump, MI myocardial infarction, Max maximum, Cr creatinine, Min minimum, CC creatinine clearance, pp per patient, Serious infectious complications Pneumonia,
Mediastinitis, Bacteremia
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did not require a prolonged hospital stay. One Jehovah’s
Witness, who underwent surgery for an off pump coron-
ary artery bypass, required 12 h of intra-aortic balloon
pump support immediately after surgery. No significant
differences were found in the lengths of the mechanical
ventilation support (p = 0.218), the intensive care unit stay
(p = 0.080), or the postoperative stay (p = 0.223, Table 4).
Only 17 of the 62 (27.4 %) control group patients were
transfused with a total of 39 units of red blood cells con-
centrates (0.63 ± 1.5 units per patient, 2.3 ± 2.2 units per
transfused patient). No Jehovah’s Witness patient was
transfused (Table 4, Figs. 1 and 2).
Discussion
In the current study we presented the outcomes after
cardiac surgery for a non-selected group of Jehovah’s
Witnesses (n = 31) operated in our cardiac surgery de-
partment from 1991 to 2012. Outcomes and demo-
graphic variables were compared with a matched control
group (n = 62) as described above. No difference was
demonstrated in terms of hospital mortality, in-hospital
morbidity, or the intensive care or hospital length of
stay. Hemoglobin levels remained similar between
groups, both pre- and postoperatively.
Previous, non-comparative studies provided evidence
that cardiac surgery can be safely performed in Jehovah’s
Witnesses, with acceptable outcomes in terms of mortal-
ity and morbidity [14–18]. Moreover, a literature search
identified four retrospective comparative studies evaluat-
ing cardiac surgery in Jehovah’s Witnesses in comparison
to a control group of patients. Three studies compared
outcomes after cardiac surgery between Jehovah’s
Witnesses and a control group of matched transfused
patients [4, 6, 7] and another one between Jehovah’s
Witnesses and a matched group regardless of blood
transfusion [5]. A comparison of the major demographic
data and surgical outcomes between our study and pre-
vious comparative studies is shown in Table 5.
Our Jehovah’s Witness group differed significantly from
other studies regarding the type of cardiac surgery proce-
dures. Patients underwent a variety of high risk surgical
procedures, including urgent operations, reoperations,
double valve surgery, combined valve and coronary sur-
gery and ascending aorta procedures (Tables 2, 5). More
precisely, in our group only 54 % of all procedures were
isolated coronary bypass surgery; whereas, El Azab et al.
[5] reported more than 90 % coronary by-pass surgeries
for the Jehovah’s Witness group. In the other three studies,
which compared Jehovah’s Witnesses to a matched
Fig. 1 Comparison of mean hemoglobin over time for Control Group transfused, Control Group not transfused, and Jehovah’s Witness patients.
(CG = Control Group, JhW = Jehovah’s Witnesses, Hb = Hemoglobin, Preop = Preoperative, CI = Confidence Intervals)
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transfused group, coronary bypass surgery accounted for
51 %, 65 %, and 78 % of all cases [4, 6, 7]. Moreover, in
our study, 10 % of all procedures were reoperations, which
were not reported in the other studies (Table 5).
Despite a trend towards more complex operations, our
results are in agreement with previous studies [4–7]. In
terms of surgical outcomes, no difference was observed
in early operative mortality. There was a trend towards a
prolonged intensive care unit length of stay for Jehovah’s
Witness group, who stayed 1.3 days more than control
group (p = 0.08). This difference was in part due to two
Jehovah’s Witnesses, who required prolonged intensive
care unit hospitalization (14 and 21 days) due to
hemoglobin values less than 5.5 g/dL during the postop-
erative period. Blood restriction was respected according
to the patient’s convictions. If these patients were excluded
from the analysis as outliners, the new intensive care unit
length of stay would be 3.4 ± 1.6 days (p = 0.215), which is
closer to control group. Nevertheless, we believe that both
values should be discussed, as the prolonged intensive
care unit stay was related to their refusal of transfusion.
Both were released from the hospital uneventfully on
postoperative day 28. Both groups of patients had equiva-
lent postoperative lengths of stay. No difference was found
with regard to perioperative and postoperative blood loss,
suggesting no preferential surgical hemostasis between
groups. Two patients had a revision for bleeding in the
Jehovah’s Witness group. The first had a preoperative
hemoglobin level of 14.4gr/dL. He was reoperated at J0
after a major operation. No apparent source of
hemorrhage was found. This patient presented after the
reoperation an hemoglobin level of 9.6gr/dL. The patient
was discharged uneventfully from the hospital at day 11.
The second patient belongs to the group of the two pa-
tients exhibiting a hemoglobin level below 5.5gr/dL. He
underwent a CABG (coronary arterial bypass graft) pro-
cedure and was been reoperated during the following
night (12 h after operation). The source of bleeding was in
the field of the dissection of the mammary artery. He had
a preoperative hemoglobin of 17.3gr/dL. The hemoglobin
level after the reoperation was 8gr/dL and at reached its
minimal levels of 5.2gr/dL at postoperative day 7. The pa-
tient was discharged at day 28. In both groups, drains
were withdrawn within the first 48 h. No difference was
revealed in terms of postoperative morbidity. The patient
who died in the Jehovah’s Witness group was a high risk
patient. Preoperative chronic renal insufficiency was the
cause of the acute renal failure observed at postoperative
Fig. 2 Histogram of transfused Red Blood Cells in Units
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Table 5 Comparison of current study with previous retrospective comparative studies
Marinakis (n = 31 JhWs
vs. 62 CG patients)
El Azab [5] (n = 123 JhWs
vs. 4219 CG patients)
Stamou [7] (n = 49 JhWs
vs. 196 transfused patients)
Bhaskar [6] (n = 49 JhWs
vs. 196 transfused patients)
Pattakos [4] (n = 322 JhWs
vs. 322 transfused patients)
Isolated CABG 15 (48 %) 112 (91 %) 38 (78 %) 25 (51 %) 209 (65 %)
Combined surgery 7 (22.6 %) 10 (8.1) 2 (4 %) 11 (22.4 %) 16 (5 %)
Reoperation 3 (9.7 %) - 0 - -
ICU LOS 4.3 ± 3.9 (p = 0.08) 2.3 ± 3.2 (p = 0.16) 1.5 ± 1.3 (p = 0.22) 1 ± 0.4 (p = 0.81) 1 (50 % perc) (p = 0.001)
In-hospital mortality 1 (3 %) (p = 0.55) 3 (2.7 %) (p = 0.59) 3 (6 %) (p = 0.63) 1 (2 %) (p = 0.52) 10 (3 %) (p = 0.40)
Postoperative infarct 0 (p = 1.00) 2 (1.8 %) (p = 0.02) 0 (p = 0.62) 0 (p = 0.62) 1 (0.3) (p = 0.01)












day one. Effectively, the mild hemodilution observed dur-
ing cardiopulmonary bypass doesn’t explain this acute
renal failure. The progressive rise in hemoglobin the week
following the operation and the occurrence of a general
sepsis after a mediastinitis at postoperative day 7 probably
exclude that this patient died because of transfusion
refusal.
No statistically significant difference was found be-
tween groups in the preoperative or postoperative period
for hemoglobin and creatinine concentrations or platelet
counts (Table 3). Among the control group, the mean
preoperative hemoglobin value was significantly less in
transfused patients (12.5 ± 2.1 g/dL versus 14.2 ± 1.3 g/dL
for the non-transfused control group, p = 0.001, Fig. 1).
This finding is indicative of the importance of “normal”
preoperative hemoglobin levels to reduce the need for red
blood cell transfusions [19]. Erythropoietin was adminis-
tered to 4 Jehovah’s Witnesses preoperatively for low
hemoglobin and to 3 more during hospitalization for the
same reason. Our center is especially interested in patient
blood management strategies; therefore, we adopted a re-
stricted transfusion policy for all the population we are
taking in charge. In this study, only 17 of 62 (27.4 %) pa-
tients in the control group were transfused with a total of
39 units of red blood cells. Eight of them received only 1
unit of red blood cells and four of them 2 units (Fig. 2).
We can reasonably assume that some patients who re-
ceived only one unit, were transfused to correct a possible
hemodilution status frequently present at least until the
3rd postoperative day. These patients could have avoided
blood transfusion if a more clinically-oriented approach
had been used. Thus, although our transfusion rate is very
competitive with regards to the literature, further im-
provement in blood saving is still possible.
Current literature reports transfusion rates from 25 %
to 95 % [1, 2, 11], with an average rate around 50 % [20].
Blood transfusion in cardiac surgery is associated with
several adverse effects. A recent meta-analysis concern-
ing the risk of red blood cell transfusions in cardiac sur-
gery reported that transfused patients are at greater risk
of developing postoperative infectious complications and
acute myocardial infarction, have prolonged length of
stay postoperatively in the intensive care unit and hos-
pital, and have increased long term mortality [1]. More-
over, red blood cell transfusion is associated with a
significantly increased hospital cost [1]. On the other
hand, there are situations where a blood transfusion is
lifesaving. It has been reported that hemoglobin levels
<7 g/dL in surgical patients who refused blood transfu-
sion, regardless of type of surgery, is associated with
higher morbidity and mortality [12]. The same study re-
ported a mortality of more than 40 % for patients with
hemoglobin levels <5 g/dL [12]. In our center, we try to
respect a threshold of 7 g/dL of hemoglobin for blood
transfusions. We accept a relative hemodilution state in
the early postoperative period when most blood loss oc-
curs, and we interrupt anti-aggregation therapy 7 days
before surgery for planned operations. In addition, we
pay major attention in controlling hypertension, espe-
cially in the early postoperative period. With this policy,
we are able to limit blood transfusion rate after cardiac
surgery to 25-30 %.
This study has two relative limitations. The first is that
our Jehovah’s Witness group is relatively small and het-
erogeneous (n = 31). On the other hand, it is an unse-
lected group as no Jehovah’s Witness was refused from
surgery in our department. In addition, the diversity of
the high risk surgical procedures, as stated above, differ-
entiates our group from those evaluated in previous
studies. The second limitation is the relatively long
period that was considered (from 1991 to 2012). We be-
lieve that the algorithm used to select the control group
(previous and next patient, of the same sex, undergoing
the same procedure) neutralized most of the time effect
in the group comparisons. Our results may not be up-
to-date with regard to absolute numbers, mainly con-
cerning the length of stay in the hospital and intensive
care unit, as there is a tendency over time for faster hos-
pital discharges, but the between groups comparisons
are probably not affected due to design of our study.
Furthermore, as our hospital has no intermediate unit
between the intensive care unit and the normal ward,
our intensive care unit length of stay is relatively pro-
longed in comparison to other studies. On the other
hand, our group of Jehovah’s Witnesses was a non-
selected group, characterized by more complex cardiac
procedures, than reported in current literature, with
10 % of reoperations.
Conclusions
The results of our study support the view that cardiac sur-
gery, including complex procedures and reoperations, can
be performed in Jehovah’s Witnesses provided rigorous
preoperative preparations, perioperative hemostasis, and
postoperative management. Moreover, we confirmed that
there is no difference in terms of early postoperative
mortality or serious morbidity between Jehovah’s Witnesses
and non-Jehovah’s Witness populations. It would be of
interest to compare the long term mortality between
Jehovah’s Witnesses and non-Jehovah’s Witnesses after
cardiac surgery in future studies.
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